217 related articles for article (PubMed ID: 10389199)
1. A new method of measuring C-reactive protein, with a low limit of detection, suitable for risk assessment of coronary heart disease.
Eda S; Kaufmann J; Molwitz M; Vorberg E
Scand J Clin Lab Invest Suppl; 1999; 230():32-5. PubMed ID: 10389199
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of an improved immunoturbidimetic assay for serum C-reactive protein on a COBAS INTEGRA 400 Analyzer.
Sánchez A; Mirabel JL; Barrenechea E; Eugui J; Puelles A; Castañeda A
Clin Lab; 2002; 48(5-6):313-7. PubMed ID: 12071582
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a sensitive immunoluminometric assay for the determination of C-reactive protein (CRP) in serum and plasma and the establishment of reference ranges for different groups of subjects.
Wood WG; Lüdemann J; Mitusch R; Heinrich J; Maass R; Frick U
Clin Lab; 2000; 46(3-4):131-40. PubMed ID: 10791120
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of two new high-sensitivity methods for C-reactive protein.
Rothkrantz-Kos S; Bekers O; Gubbels A; Drent M; Schmitz MP; van Dieijen-Visser MP
Ann Clin Biochem; 2003 Jul; 40(Pt 4):398-405. PubMed ID: 12880542
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 3 automated assays for C-reactive protein in end-stage renal disease: clinical and epidemiological implications.
Maggiore U; Cristol JP; Canaud B; Dupuy AM; Formica M; Pozzato M; Panichi V; Consani C; Metelli MR; Sereni L; De Nitti C; David S; Tetta C
J Lab Clin Med; 2005 Jun; 145(6):305-8. PubMed ID: 15976758
[TBL] [Abstract][Full Text] [Related]
6. Serum amyloid A, C-reactive protein and remnant-like lipoprotein particle cholesterol in type 2 diabetic patients with coronary heart disease.
Hamano M; Saito M; Eto M; Nishimatsu S; Suda H; Matsuda M; Matsuki M; Yamamoto S; Kaku K
Ann Clin Biochem; 2004 Mar; 41(Pt 2):125-9. PubMed ID: 15025802
[TBL] [Abstract][Full Text] [Related]
7. An improved assay for the determination of C-reactive protein.
Hafner G; Larkin T; Peetz D; Erbes H; Eyres H; Wrynn K; Lackner KJ
Clin Lab; 2002; 48(7-8):369-76. PubMed ID: 12146570
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of immunoturbidimetric specific protein methods using the Architect ci8200: comparison with immunonephelometry.
Denham E; Mohn B; Tucker L; Lun A; Cleave P; Boswell DR
Ann Clin Biochem; 2007 Nov; 44(Pt 6):529-36. PubMed ID: 17961307
[TBL] [Abstract][Full Text] [Related]
9. Quality specifications and the assessment of the biochemical risk of atherosclerosis.
Rifai N; Warnick GR
Clin Chim Acta; 2004 Aug; 346(1):55-64. PubMed ID: 15234636
[TBL] [Abstract][Full Text] [Related]
10. [HS CRP with Fumouze immunoturbidimetry and Dade Behring immunonephelemetry].
Onraed B; Hennache B
Ann Biol Clin (Paris); 2005; 63(3):339-44. PubMed ID: 15951269
[TBL] [Abstract][Full Text] [Related]
11. Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range.
Eda S; Kaufmann J; Roos W; Pohl S
J Clin Lab Anal; 1998; 12(3):137-44. PubMed ID: 9591699
[TBL] [Abstract][Full Text] [Related]
12. Comparison of high-sensitivity C-reactive protein serum assay results obtained using Dade-Behring BNII nephelometer and Ortho Vitros FS 5.1 clinical analyzer in respect of CRP-related risk assessment of chronic metabolic diseases.
Kusnierz-Cabala B; Gernand W; Zabek-Adamska A; Tokarz A; Naskalski JW
Clin Lab; 2008; 54(9-10):341-6. PubMed ID: 19097491
[TBL] [Abstract][Full Text] [Related]
13. Analytical performance of the Synchron LX20 Pro, BN trade mark II and IMMAGE high sensitivity C-reactive protein assays and concordance in cardiovascular risk stratification.
McWhorter VC; Ford LC; Butch AW
Clin Chim Acta; 2004 Sep; 347(1-2):71-9. PubMed ID: 15313143
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study.
Cushman M; Arnold AM; Psaty BM; Manolio TA; Kuller LH; Burke GL; Polak JF; Tracy RP
Circulation; 2005 Jul; 112(1):25-31. PubMed ID: 15983251
[TBL] [Abstract][Full Text] [Related]
15. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey.
Miller M; Zhan M; Havas S
Arch Intern Med; 2005 Oct; 165(18):2063-8. PubMed ID: 16216995
[TBL] [Abstract][Full Text] [Related]
16. High-sensitivity C-reactive protein in children at risk for coronary artery disease.
Guran O; Akalin F; Ayabakan C; Dereli FY; Haklar G
Acta Paediatr; 2007 Aug; 96(8):1214-9. PubMed ID: 17655623
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Denka-Seiken turbidimetric high-sensitivity C-reactive protein assay.
Sung HJ; Kim JH; Park R; Lee KR; Kwon OH
Clin Chem Lab Med; 2002 Aug; 40(8):840-5. PubMed ID: 12392316
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of the analytical performances of CRP Diasys reagent on Roche Hitachi 917].
Pachot M; Péronnet F; Villard C; Bayle A
Ann Biol Clin (Paris); 2006; 64(4):335-9. PubMed ID: 16829477
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
Sabatine MS; Morrow DA; Jablonski KA; Rice MM; Warnica JW; Domanski MJ; Hsia J; Gersh BJ; Rifai N; Ridker PM; Pfeffer MA; Braunwald E;
Circulation; 2007 Mar; 115(12):1528-36. PubMed ID: 17372173
[TBL] [Abstract][Full Text] [Related]
20. [The laser nephelometric determination of C-reactive protein].
Wulf E; Saemann KE; Pfeifer HJ
Z Med Lab Diagn; 1989; 30(5):264-8. PubMed ID: 2506703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
